<HashMap><database>biostudies-arrayexpress</database><scores/><additional><omics_type>Metabolomics</omics_type><omics_type>Unknown</omics_type><omics_type>Transcriptomics</omics_type><omics_type>Genomics</omics_type><omics_type>Proteomics</omics_type><submitter>Yinuo Ma</submitter><instrument_platform>NA</instrument_platform><instrument_platform>Illumina NovaSeq 6000</instrument_platform><study_type>RNA-seq of total RNA</study_type><organism>Mus musculus</organism><species>Mus musculus</species><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/E-MTAB-16488</full_dataset_link><description>This study aimed to investigate the transcriptional effects of asperuloside (ASP) on inflammatory chondrocytes and its potential mechanisms in osteoarthritis (OA). ATDC5 cells were stimulated with TNF-α and IL-1β to mimic the inflammatory environment of OA, followed by treatment with either asperuloside (ASP) or PBS as a vehicle control. An untreated group served as a baseline control. Total RNA was extracted and subjected to RNA-seq to identify differentially expressed genes and pathways involved in inflammation, extracellular matrix metabolism, and cartilage homeostasis. The results provide transcriptomic insights into the anti-inflammatory and chondroprotective effects of asperuloside.</description><repository>biostudies-arrayexpress</repository><sample_protocol>Library Construction - RNA-seq libraries were prepared from 1 µg of total RNA using the Illumina TruSeq Stranded mRNA Library Prep Kit (Illumina, USA) following the manufacturer’s protocol.  After adapter ligation and PCR amplification, libraries were quantified and validated using a Qubit fluorometer and Agilent Bioanalyzer.</sample_protocol><sample_protocol>Nucleic Acid Extraction - Total RNA was extracted from ATDC5 cells using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions.  RNA concentration and purity were assessed using a NanoDrop spectrophotometer, and RNA integrity was confirmed with an Agilent 2100 Bioanalyzer (RIN ≥ 8.0).</sample_protocol><sample_protocol>Sample Collection - ATDC5 cells were cultured under standard conditions (37°C, 5% CO₂) in DMEM/F12 medium supplemented with 5% FBS and antibiotics.  Cells were divided into three groups: untreated control, TNF-α/IL-1β–stimulated group (OA model), and TNF-α/IL-1β–stimulated group treated with asperuloside (ASP).  After 24 hours of treatment, cells were harvested for RNA extraction.</sample_protocol><sample_protocol>Sequencing - Sequencing was performed on an Illumina NovaSeq 6000 platform using paired-end 150 bp reads (PE150).  Raw reads were subjected to quality control, including adapter trimming and low-quality base removal, before downstream analysis.</sample_protocol><figure_sub>Organization</figure_sub><figure_sub>MINSEQE Score</figure_sub><figure_sub>Assays and Data</figure_sub><figure_sub>MAGE-TAB Files</figure_sub><pubmed_authors>Yinuo Ma</pubmed_authors></additional><is_claimable>false</is_claimable><name>RNA-seq of ATDC5 chondrocytes treated with asperuloside under TNF-α and IL-1β stimulation compared with PBS-treated and untreated controls</name><description>This study aimed to investigate the transcriptional effects of asperuloside (ASP) on inflammatory chondrocytes and its potential mechanisms in osteoarthritis (OA). ATDC5 cells were stimulated with TNF-α and IL-1β to mimic the inflammatory environment of OA, followed by treatment with either asperuloside (ASP) or PBS as a vehicle control. An untreated group served as a baseline control. Total RNA was extracted and subjected to RNA-seq to identify differentially expressed genes and pathways involved in inflammation, extracellular matrix metabolism, and cartilage homeostasis. The results provide transcriptomic insights into the anti-inflammatory and chondroprotective effects of asperuloside.</description><dates><release>2026-07-01T00:00:00Z</release><modification>2026-07-01T01:04:19.702Z</modification><creation>2026-01-02T14:52:38.201Z</creation></dates><accession>E-MTAB-16488</accession><cross_references><ENA>ERP187206</ENA><EFO>EFO_0002944</EFO><EFO>EFO_0004170</EFO><EFO>EFO_0009653</EFO><EFO>EFO_0005518</EFO><EFO>EFO_0004184</EFO></cross_references></HashMap>